The FDA approves BrainSense Adaptive deep brain stimulation and electrode identifier technology for the treatment of ...
BrainSense Adaptive deep brain stimulation (aDBS) and BrainSense Electrode Identifier (EI) for patients with Parkinson’s ...
The company's adaptive deep brain stimulation technology for Parkinson's disease therapy is expected to be available ...
The BrainSense adaptive deep brain stimulation system personalizes therapy by dynamically adjusting stimulation based on real ...
(NYSE: MDT) announced today that the FDA approved its BrainSense adaptive deep brain stimulation (aDBS) platform.
For the one million people diagnosed with Parkinson's disease in the United States1, Medtronic plc (NYSE:MDT), a global ...
Medtronic (MDT) announced FDA approval of BrainSense Adaptive deep brain stimulation – aDBS – and BrainSense Electrode Identifier. There is no cure for debilitating neurological conditions like ...
After decades of development and trials, Medtronic has secured U.S. Food and Drug Administration approval for adaptive ...
The FDA has approved BrainSense, an adaptive deep brain stimulation system that can adjust therapy for Parkinson’s disease in ...
Medtronic's FDA-approved BrainSense Adaptive DBS system revolutionizes Parkinson's therapy with real-time adjustments for ...
T here is still no cure for Parkinson’s disease, but the U.S. Food and Drug Administration (FDA) approved a new deep brain ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results